Conatus Pharmaceuticals Inc. (CNAT)

[Inoviorulez]

Buyout offer would have probably been too low for management. As for why? The company indicated that Emricasan can be indicated for other liver disease and rare diseases. That means that the money it takes from the deal it can apply to other new pipeline drugs to enhance shareholder value. A buyout offer for Emricasan dealing with both NASH Fibrosis and NASH cirhossis would have been at least $3B which no pharma would pay for in only phase 2b of testing. Think about it TBRA only targets NASH fibrosis and not Cirhossis and was bought out for $1.7B